Bioventus, a leader in orthobiologic solutions, today announced promotions to its executive leadership team. Effective immediately Andrew Hosmer is promoted to Managing Director, International with responsibility for Europe, Middle East and Africa as well as the international Headquarters office Amsterdam. In addition, Isabelle Levy-Unger is promoted to Managing Director, International with responsibility for Canada, Latin America and Asia Pacific. Both have been serving as Interim Managing Directors since October 2014 and will report to CEO Tony Bihl. Hosmer and Levy-Unger are responsible for growing the Bioventus Active Healing Therapies suite of products worldwide.
This Smart News Release features multimedia. View the full release here: https://www.businesswire.com/news/home/20150610005202/en/
“International expansion is a strategic imperative for Bioventus and since 2012 the company has grown its presence in more than 25 countries,” said Tony Bihl.“Andrew and Isabelle will be counted on to continue to lead our sales and marketing efforts in these international markets and to accelerate our expansion in additional major markets worldwide.”
Bioventus will continue to operate its international business from Amsterdam, The Netherlands, utilizing its common business support functions for customer service, finance, training, human resources, marketing, and supply chain.
Hosmer previously served as Director of European Sales for Bioventus helping the company establish its international sales and operations presence and has been with Bioventus since its inception in May of 2012. He worked for Smith & Nephew from 2005 to 2012, first serving as a Sales Representative and Field Trainer from 2005 to 2007 and then from 2007 to 2010 as Director of Sales Training and Operations for the company’s Biologics & Spine business. He served as Director of Canadian Commercialization for the Biologics & Spine business of Smith & Nephew from 2010 until the spring of 2012. Prior to that, Hosmer held sales roles with Bradley Pharmaceuticals and Insl-X. He holds a Master of Arts in industrial/organizational psychology from Adelphi University and a Bachelor of Arts in sociology from Ithaca College.
Levy-Unger joined Bioventus in April 2013 and previously served as its Director of International Commercial Operations for the Americas and as Director of Operational Excellence. Prior to joining Bioventus, she worked for 13 years at Grifols, Inc., formerly Talecris Biotherapeutics and Bayer Biological, where she served in global sales and marketing roles from 1999 to 2004 when she was appointed to lead the transition activities for the divestiture of the business from Bayer to Talecris which concluded in 2005. At Talecris, she served as Director of European Commercial Operations and later as Senior Director of International Operations before being promoted to Head of Sales. Earlier in her career she also held sales and marketing roles with Reichhold Chemicals.
Levy-Unger is fluent in three languages and holds a postgraduate degree in negotiation and international business from the University of Paris, La Sorbonne; a master’s degree in international business, a Bachelor of Arts in marketing, and a baccalaureate in economics the University of Le Havre, France. In addition, she has studied management and marketing, communications and English and Spanish at Appalachian State University in Boone, NC.
Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical, that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.
View source version on businesswire.com: https://www.businesswire.com/news/home/20150610005202/en/
MULTIMEDIA AVAILABLE :